MA47576A - Composés inhibiteurs d'oga bicyclique - Google Patents
Composés inhibiteurs d'oga bicycliqueInfo
- Publication number
- MA47576A MA47576A MA047576A MA47576A MA47576A MA 47576 A MA47576 A MA 47576A MA 047576 A MA047576 A MA 047576A MA 47576 A MA47576 A MA 47576A MA 47576 A MA47576 A MA 47576A
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16204834 | 2016-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47576A true MA47576A (fr) | 2020-01-01 |
Family
ID=57570521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047576A MA47576A (fr) | 2016-12-16 | 2017-12-15 | Composés inhibiteurs d'oga bicyclique |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190359609A1 (fr) |
EP (1) | EP3555094A1 (fr) |
JP (1) | JP2020503300A (fr) |
CN (1) | CN110312716A (fr) |
AU (1) | AU2017378182A1 (fr) |
CA (1) | CA3044762A1 (fr) |
MA (1) | MA47576A (fr) |
WO (1) | WO2018109198A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
WO2017076900A1 (fr) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | Composé [1,2,4]triazolo[1,5-a]pyridmidine-7-yl |
EP3419972B1 (fr) | 2016-02-25 | 2023-07-26 | Asceneuron SA | Inhibiteurs de glycosidases |
CN109071526B (zh) | 2016-02-25 | 2023-02-28 | 阿森纽荣股份公司 | 哌嗪衍生物的酸加成盐 |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
JP2019510006A (ja) | 2016-02-25 | 2019-04-11 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
KR20190071721A (ko) | 2016-11-02 | 2019-06-24 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
EP3535267B1 (fr) | 2016-11-02 | 2020-12-30 | Janssen Pharmaceutica NV | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine comme inhibiteurs de pde2 |
CN109890824B (zh) | 2016-11-02 | 2022-05-24 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
US20200157092A1 (en) * | 2017-02-27 | 2020-05-21 | Janssen Pharmaceutlca NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
WO2019037860A1 (fr) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | Inhibiteurs linéaires de la glycosidase |
US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
EP3765458B1 (fr) * | 2018-03-14 | 2023-01-11 | Biogen MA Inc. | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase |
ES2939043T3 (es) * | 2018-07-31 | 2023-04-18 | Lilly Co Eli | Compuestos de 5-metil-4-fluoro-tiazol-2-ilo |
WO2020039029A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Composés spiro utilisés en tant qu'inhibiteurs de glycosidases |
WO2020039028A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de tétrahydro-benzoazépine glycosidase |
AU2019344922A1 (en) * | 2018-09-19 | 2021-03-25 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
TWI716107B (zh) | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
JP2022510430A (ja) * | 2018-12-05 | 2022-01-26 | バイオジェン・エムエイ・インコーポレイテッド | モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤 |
IL293931A (en) * | 2019-12-18 | 2022-08-01 | Janssen Pharmaceutica Nv | oga inhibitor compounds |
KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
WO2024081775A1 (fr) | 2022-10-14 | 2024-04-18 | Eli Lilly And Company | Synthèse de composés 6-fluoro-2-méthylbenzo[d] thiazol-5-yle |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2582473T3 (es) * | 2011-12-06 | 2016-09-13 | Janssen Pharmaceutica, N.V. | Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2H-[1,4]oxazin-3-amina para el tratamiento de trastornos en que está implicada la beta-secretasa |
ES2723883T3 (es) * | 2013-03-14 | 2019-09-03 | Merck Patent Gmbh | Inhibidores de glicosidasa |
JP6626449B2 (ja) * | 2014-04-23 | 2019-12-25 | ダート・ニューロサイエンス・(ケイマン)・リミテッド | PDE2阻害剤としての置換[1,2,4]トリアゾロ[1,5−a]ピリミジン−7−イル化合物 |
BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
WO2017035114A1 (fr) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Dérivés de benzimidazole utiles à titre d'agonistes inverses de cb-1 |
WO2017076900A1 (fr) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | Composé [1,2,4]triazolo[1,5-a]pyridmidine-7-yl |
-
2017
- 2017-12-15 WO PCT/EP2017/083125 patent/WO2018109198A1/fr unknown
- 2017-12-15 US US16/469,685 patent/US20190359609A1/en not_active Abandoned
- 2017-12-15 CN CN201780086726.3A patent/CN110312716A/zh active Pending
- 2017-12-15 MA MA047576A patent/MA47576A/fr unknown
- 2017-12-15 CA CA3044762A patent/CA3044762A1/fr active Pending
- 2017-12-15 EP EP17825805.9A patent/EP3555094A1/fr not_active Withdrawn
- 2017-12-15 JP JP2019532020A patent/JP2020503300A/ja active Pending
- 2017-12-15 AU AU2017378182A patent/AU2017378182A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2018109198A1 (fr) | 2018-06-21 |
EP3555094A1 (fr) | 2019-10-23 |
US20190359609A1 (en) | 2019-11-28 |
JP2020503300A (ja) | 2020-01-30 |
AU2017378182A1 (en) | 2019-06-06 |
CN110312716A (zh) | 2019-10-08 |
CA3044762A1 (fr) | 2018-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
MA47131A (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
DK3692040T3 (da) | Kemiske forbindelser | |
MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
MA52942A (fr) | Composés inhibiteurs d'oga | |
MA46228A (fr) | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll | |
MA44233A (fr) | Nouveaux composés | |
MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
DK3436444T3 (da) | Heterocyklisk forbindelse | |
MA52939A (fr) | Composés inhibiteurs d'oga | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA47420A (fr) | Composés inhibiteurs d'oga | |
MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
DK3612519T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
DK3562487T3 (da) | Metalloenzyminhibitorforbindelser | |
DK3737677T3 (da) | Tetrahydroisoquinolinforbindelser | |
DK3183242T3 (da) | Substituerede bicykliske forbindelser |